Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

This study is a multicenter, prospective, randomized phase II trial aimed at exploring the value of adjuvant radiotherapy in patients at high risk of recurrence after neoadjuvant chemoradiotherapy for esophageal cancer. The study primarily includes patients with esophageal cancer who underwent neoadjuvant chemoradiotherapy and surgery and did not achieve complete pathological response (non-pCR) postoperatively and were defined as preoperative clinical stage at T3-4N+M0. Eligible patients will be randomized in a 1:1 ratio into two groups: the observation group and the adjuvant radiotherapy gro

Trial Details

NCT ID
NCT06272214
Phase
PHASE2
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Adjuvant radiotherapy
  • Observation
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Able to understand and voluntarily sign the written informed consent form, which must be signed before the specified research procedures required b…
  • Subjects in this study are male or female aged ≥18 and ≤75 years at the time of signing the informed consent form.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 or Karnofsky Performance Status (KPS) score ≥80 points (see Table 1) at the tim…
  • Histologically confirmed esophageal squamous cell carcinoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →